timothy sykes logo
BIAF Stock Draws Traders As CyPath Lung Growth Accelerates Thumbnail
G Google News

BIAF Stock Draws Traders As CyPath Lung Growth Accelerates

ELLIS HOBBS•UPDATED OCT. 8, 2026, 8:32 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

bioAffinity Technologies Inc. stocks have been trading up by 10.1 percent following bullish sentiment around its latest diagnostic developments

Key Takeaways

  • CyPath Lung test volumes more than doubled year over year through Q3 2026, as ordering offices jumped 89% and existing users increased utilization 48%.
  • A new Hong Kong patent for CyPath Lung strengthens bioAffinity Technologies’ Asia IP moat alongside an existing China patent.
  • A nationwide AvMEDICAL deal targets VA and federal healthcare systems, aiming to push CyPath Lung deeper into the veteran community.
  • New NAVREF data for CyPath Lung highlight high sensitivity, specificity, and potential cost savings in a 2,000‑patient veteran and military study.
  • Nasdaq compliance has been restored for BIAF shares and warrants, removing an immediate delisting overhang and stabilizing the trading backdrop.

Candlestick Chart

Live Update At 08:32:15 EDT: On Thursday, October 08, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 10.1%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIAF has started acting like a classic small‑cap biotech momentum name. On the chart, bioAffinity Technologies has pulled back from a spike above $10 in late 2026/09 to the mid‑$6 range by 2026/10/07, but it is still holding well above prior lows. That tells traders the initial surge has cooled, yet buyers remain active on dips.

The daily candles show wide trading ranges — for example, on 2026/09/18 BIAF traded between $9.23 and $12.48 before closing at $9.43. Moves like that scream volatility. Intraday 5‑minute data back it up, with pre‑market swings from the low‑$6s to near $8 in less than an hour. For short‑term traders, BIAF is a vehicle, not a sleepy hold.

More Breaking News

Fundamentals show a typical early‑stage commercial story. bioAffinity Technologies generated about $6.1M in revenue with a strong 52.6% gross margin, but massive negative margins and returns reflect heavy spending and small scale. The company burned roughly $3.2M in operating cash in the latest quarter and stayed afloat by raising about $2.7M through stock issuance. BIAF carries modest debt and a current ratio of 1.4, which gives some breathing room. For traders, this is a dilution‑risk, high‑growth setup where news flow and volume matter more than traditional earnings metrics.

Why Traders Are Watching BIAF Right Now

BIAF has quickly become one of those tickers that lights up scanners on both news and volume. The big driver is CyPath Lung, bioAffinity Technologies’ noninvasive lung‑cancer test. Through Q3 2026, the company more than doubled test sales versus 2025. Volumes climbed from 775 tests to over 1,620, while the number of ordering physician offices jumped 89%. Even more important, existing prescribers increased utilization by 48%. That tells traders this is not just a one‑and‑done launch; usage is deepening where CyPath Lung is already in play.

When bioAffinity Technologies secured a Hong Kong patent for its CyPath Lung platform, following an earlier China patent, the market reaction was loud. BIAF ripped roughly 59% on a surge in trading volume, a clear sign this stock is hypersensitive to IP and commercialization milestones. For momentum traders, that Hong Kong move is the blueprint: clear catalyst, big volume, outsized price reaction.

The AvMEDICAL deal adds another layer. bioAffinity Technologies signed a nationwide federal healthcare distribution agreement that targets the U.S. Department of Veterans Affairs and other federal systems. BIAF and AvMEDICAL have already taken CyPath Lung in front of more than 300 physicians and VA leaders, showing this is not a paper‑only partnership. Combined with NAVREF presentations highlighting strong clinical performance, the 2,000‑patient FlowPath Lung veteran/military study, and potential cost savings, BIAF is telling a story that resonates with large, centralized buyers.

Add in restored Nasdaq compliance for BIAF and its warrants, and one key overhang has cleared. With delisting fears eased, traders can refocus on catalysts, volume, and how far this early commercial ramp can run.

Conclusion

For active traders, BIAF sits at the intersection of story and volatility. bioAffinity Technologies is still losing money and burning cash, but the growth in CyPath Lung test usage is real, and the company has lined up meaningful levers: a growing base of pulmonology and oncology practices, a federal channel via AvMEDICAL, and expanding IP protection across China and Hong Kong. That mix gives BIAF a steady stream of potential catalysts.

At the same time, the tape reminds everyone this is not a slow grind higher. BIAF has already shown it can jump nearly 60% on a single patent headline and then retrace, creating opportunity for disciplined traders and pain for anyone chasing without a plan. Liquidity is supported by the Nasdaq listing, but dilution and cash burn remain part of the story as bioAffinity Technologies funds its expansion.

This is exactly the kind of chart‑plus‑news setup the Sykes community studies every day. As Tim Sykes likes to say, “Volatility is only your friend if you respect it with strict rules and quick cuts.” As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. For traders tracking BIAF, that means riding the catalysts, watching the level‑2 and volume, and never forgetting that small‑cap biotech momentum can reverse just as fast as it ramps. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”